Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion

Alessia Zoso, Emilia M C Mazza, Silvio Bicciato, Susanna Mandruzzato, Vincenzo Bronte, Paolo Serafini, Luca A Inverardi

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

By restraining T-cell activation and promoting Treg-cell expansion, myeloid-derived suppressor cells (MDSCs) and tolerogenic DCs can control self-reactive and antigraft effector T cells in autoimmunity and transplantation. Their therapeutic use and characterization, however, is limited by their scarce availability in the peripheral blood of tumor-free donors. In the present study, we describe and characterize a novel population of human myeloid suppressor cells, named fibrocytic MDSC, which are differentiated from umbilical cord blood precursors by 4-day culture with FDA-approved cytokines (recombinant human-GM-CSF and recombinant human-G-CSF). This MDSC subset, characterized by the expression of MDSC-, DC-, and fibrocyte-associated markers, promotes Treg-cell expansion and induces normoglycemia in a xenogeneic mouse model of Type 1 diabetes. In order to exert their protolerogenic function, fibrocytic MDSCs require direct contact with activated T cells, which leads to the production and secretion of IDO. This new myeloid subset may have an important role in the in vitro and in vivo production of Treg cells for the treatment of autoimmune diseases, and in either the prevention or control of allograft rejection.

Original languageEnglish
Pages (from-to)3307-3319
Number of pages13
JournalEuropean Journal of Immunology
Volume44
Issue number11
DOIs
StatePublished - Jan 1 2014

Fingerprint

Regulatory T-Lymphocytes
T-Lymphocytes
Therapeutic Uses
Granulocyte Colony-Stimulating Factor
Myeloid Cells
Granulocyte-Macrophage Colony-Stimulating Factor
Autoimmunity
Type 1 Diabetes Mellitus
Fetal Blood
Autoimmune Diseases
Allografts
Transplantation
Myeloid-Derived Suppressor Cells
Cytokines
Population
Neoplasms

Keywords

  • Fibrocytes
  • Genomic analysis
  • IDO
  • Myeloid-derived suppressor cells
  • Treg cells
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. / Zoso, Alessia; Mazza, Emilia M C; Bicciato, Silvio; Mandruzzato, Susanna; Bronte, Vincenzo; Serafini, Paolo; Inverardi, Luca A.

In: European Journal of Immunology, Vol. 44, No. 11, 01.01.2014, p. 3307-3319.

Research output: Contribution to journalArticle

Zoso, Alessia ; Mazza, Emilia M C ; Bicciato, Silvio ; Mandruzzato, Susanna ; Bronte, Vincenzo ; Serafini, Paolo ; Inverardi, Luca A. / Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. In: European Journal of Immunology. 2014 ; Vol. 44, No. 11. pp. 3307-3319.
@article{12c513616666452d8bbfa23528861aa7,
title = "Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion",
abstract = "By restraining T-cell activation and promoting Treg-cell expansion, myeloid-derived suppressor cells (MDSCs) and tolerogenic DCs can control self-reactive and antigraft effector T cells in autoimmunity and transplantation. Their therapeutic use and characterization, however, is limited by their scarce availability in the peripheral blood of tumor-free donors. In the present study, we describe and characterize a novel population of human myeloid suppressor cells, named fibrocytic MDSC, which are differentiated from umbilical cord blood precursors by 4-day culture with FDA-approved cytokines (recombinant human-GM-CSF and recombinant human-G-CSF). This MDSC subset, characterized by the expression of MDSC-, DC-, and fibrocyte-associated markers, promotes Treg-cell expansion and induces normoglycemia in a xenogeneic mouse model of Type 1 diabetes. In order to exert their protolerogenic function, fibrocytic MDSCs require direct contact with activated T cells, which leads to the production and secretion of IDO. This new myeloid subset may have an important role in the in vitro and in vivo production of Treg cells for the treatment of autoimmune diseases, and in either the prevention or control of allograft rejection.",
keywords = "Fibrocytes, Genomic analysis, IDO, Myeloid-derived suppressor cells, Treg cells, Type 1 diabetes",
author = "Alessia Zoso and Mazza, {Emilia M C} and Silvio Bicciato and Susanna Mandruzzato and Vincenzo Bronte and Paolo Serafini and Inverardi, {Luca A}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/eji.201444522",
language = "English",
volume = "44",
pages = "3307--3319",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "11",

}

TY - JOUR

T1 - Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion

AU - Zoso, Alessia

AU - Mazza, Emilia M C

AU - Bicciato, Silvio

AU - Mandruzzato, Susanna

AU - Bronte, Vincenzo

AU - Serafini, Paolo

AU - Inverardi, Luca A

PY - 2014/1/1

Y1 - 2014/1/1

N2 - By restraining T-cell activation and promoting Treg-cell expansion, myeloid-derived suppressor cells (MDSCs) and tolerogenic DCs can control self-reactive and antigraft effector T cells in autoimmunity and transplantation. Their therapeutic use and characterization, however, is limited by their scarce availability in the peripheral blood of tumor-free donors. In the present study, we describe and characterize a novel population of human myeloid suppressor cells, named fibrocytic MDSC, which are differentiated from umbilical cord blood precursors by 4-day culture with FDA-approved cytokines (recombinant human-GM-CSF and recombinant human-G-CSF). This MDSC subset, characterized by the expression of MDSC-, DC-, and fibrocyte-associated markers, promotes Treg-cell expansion and induces normoglycemia in a xenogeneic mouse model of Type 1 diabetes. In order to exert their protolerogenic function, fibrocytic MDSCs require direct contact with activated T cells, which leads to the production and secretion of IDO. This new myeloid subset may have an important role in the in vitro and in vivo production of Treg cells for the treatment of autoimmune diseases, and in either the prevention or control of allograft rejection.

AB - By restraining T-cell activation and promoting Treg-cell expansion, myeloid-derived suppressor cells (MDSCs) and tolerogenic DCs can control self-reactive and antigraft effector T cells in autoimmunity and transplantation. Their therapeutic use and characterization, however, is limited by their scarce availability in the peripheral blood of tumor-free donors. In the present study, we describe and characterize a novel population of human myeloid suppressor cells, named fibrocytic MDSC, which are differentiated from umbilical cord blood precursors by 4-day culture with FDA-approved cytokines (recombinant human-GM-CSF and recombinant human-G-CSF). This MDSC subset, characterized by the expression of MDSC-, DC-, and fibrocyte-associated markers, promotes Treg-cell expansion and induces normoglycemia in a xenogeneic mouse model of Type 1 diabetes. In order to exert their protolerogenic function, fibrocytic MDSCs require direct contact with activated T cells, which leads to the production and secretion of IDO. This new myeloid subset may have an important role in the in vitro and in vivo production of Treg cells for the treatment of autoimmune diseases, and in either the prevention or control of allograft rejection.

KW - Fibrocytes

KW - Genomic analysis

KW - IDO

KW - Myeloid-derived suppressor cells

KW - Treg cells

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84916908891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916908891&partnerID=8YFLogxK

U2 - 10.1002/eji.201444522

DO - 10.1002/eji.201444522

M3 - Article

C2 - 25113564

AN - SCOPUS:84916908891

VL - 44

SP - 3307

EP - 3319

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 11

ER -